Paediatric Type 2 Diabetes – medical treatment: funding, shortage of GLP1RA, complications, surgery

Evelien Gevers

Consultant Paediatric Endocrinologist, Honorary Reader Barts Health NHS Trust – Royal London Hospital (RLH)

William Harvey Research Institute, Queen Mary University of London



Evelien.gevers@nhs.net

Helping all children and young people with diabetes in East London to lead a healthy, happy life.



Outline

- Funding of new drugs
- GLP1RA shortage
- Treatment of complications
- Bariatric surgery

Funding of NICE approved medication

NICE Technology Appraisal (TA)

- Recommendation regarding new or existing drugs or treatment in the NHS
- High-cost drugs will be funded through NHS-E or ICB.
- Obligation of hospital to put drug on their formulary.
- Hospital can claim money back

NICE guideline (NG) (eg Type 1 and 2 diabetes in CYP)

- Guidance for management of a condition, drugs not funded by NHS-E or ICB
- Inclusion in formulary needs assessment by clinicians and pharmacy → Regional (eg
 North East London) Formulary and Pathway Group (FPG) (was DTC)
- FPG will have discussions with ICB regarding funding
- Chairman's action (Chairman of Hospital Drugs and Therapeutics Committee)
 - Request/approval for individual funding of a drug by the hospital (max 5 patients)

Funding of medication

- Know your specialist paediatric pharmacist
- Find out if you have a 'Chairman's action request' and application form
- Know your Lead Formulary and Pathways Pharmacist in Trust/Hospital
- Have application form for inclusion of a drug on the formulary
- Work with your specialist paediatric pharmacist to apply for inclusion in formula
 - Sometimes 'add on' for paediatrics possible if drug already on formulary for adults.
 - Needs literature, guidance, expected numbers in next 3 years, costs.
- Form will go to Lead Formulary Pharmacist
- Invitation for discussion at FPG (Formulary and Pathway Group)/DTC
- Know your ICB and the Lead for Medicine (Diabetes) at the ICB

GLP1RA shortage memo

Likely to last until end 2024. Shortage of all types of GLP1RAs

Patient Cohort	Management Plan		
New patients	 Do NOT initiate patients on GLP-1 receptor agonists for the duration of the shortage. Optimise current treatment regimens in line with clinical guidance (<u>NICE NG28</u> or <u>NICE CG189</u>). 		
Patients currently on a GLP-1 receptor agonist	 Must only be used for licensed indications Patients established on GLP-1 RAs should be prioritised for review in line with clinical guidance Stop treatment in patients who have not achieved treatment targets (as outlined in NICE NG28 or NICE CG189). Other considerations: Do not switch between different brands of GLP-1 RAs (including between injectables and oral preparations) Do not double up a lower dose preparation where a higher dose preparation is not available Do not prescribe excessive quantities of GLP-1 RAs Support patients to access structured education and weight management programmes (where available) If switching a patient with type 2 diabetes on to insulin, ensure the chosen insulin is available as per SPS guidance 		

Complications in T2D vs T1D

- Median HbA1c for T2D was 50.0 mmol/mol (53.0 mmol/mol in 2020/21).
- 33.0% of T2D aged 12 and above received all six 'key' health checks (59.7% in T1D)

Most complications of diabetes/obesity more common in T2D than in T1D:

	T2D 2021-22	T2D 2020-21	T1D 2021-22	T1D 2020-21
BP >98 th centile	46.1%	49.3%	29.9%	30.1%
Cholesterol > 5	27.9%	26.8%	19.0%	19.8%
BMI >85 th centile	92.8%	92.0%	42.3%	42.9%
retinopathy	8.4%	3.9%	11.4 %	16.9%
albuminuria	20.6%	23.4%	11.5%	10.3%

Treatment of complications (RLH/ACDC)

Hypertension

- BP > 95th centile for height and sex on 3 occasions, 24 hr BP if possible
- First line: focus on weight loss, exercise, and reduced salt intake
- Second line if after 6 months no effect: start ACE inhibitor (eg lisinopril 5-10 mg, max 80mg)
- Aim for BP < 90th centile

Dyslipidaemia

- If abnormal, focus on dietary modification and improvement of hyperglycaemia
- If after 6 months LDL still >3.4 mmol/L, start statin (eg atorvastatin 10 mg OD)
- Aim for LDL <2.6 mmol/L and increase statins accordingly 3 monthly or refer
- If persistent hypertriglyceridaemia, consider fibrate treatment (with lipid specialist)

Treatment of complications (RLH/ACDC)

NAFLD

- If fatty liver on US, aim for weight loss and optimizing glycaemia
- Yearly US and consider referral gastro-enterologist if not improving
- Refer to gastro-enterologist if ALT > 2-3x upper normal range

Albuminuria


- If spot urine albumen/creat ratio 3-30 mg/mmol, repeat on 2 early morning samples within 3-6 months
- If continuing abnormal, despite lifestyle measures, start ACE inhibitor (lisinopril, enalapril)
- Refer to nephrology, if urine alb/creat > 30 mg/mmol


Obstructive sleep apnoea


Refer to respiratory sleep specialist

Last but not least... bariatric surgery

- Indication: BMI > 35 kg/m2 with complications of overweight such as T2D and no effect of treatment for 12-18 months
- Bariatric surgery is extremely effective
- Leads to remission of T2D in most patients
- Reduces hypertension and retinopathy
- More reduction of complications of obesity by bariatric surgery in CYP compared to adults







• QUESTIONS?

Barts Health Paediatric Diabetes Team




Type 2 focus group


Evelien Gevers, consultant Nicky Moore, Band 8 PDSN Waseema Skogen, dietitian Elizabeth Nash, psychologist Nish Patel, database manager Yasmin Khatun, database admin Maggie Murphy, secretary

Current consultants RLH

Evelien Gevers (Lead T2)
Ruben Willemsen (Lead T1)
Claire Hughes
Pratik Shah
Rathi Prasad

Estimated years of life lost increase with earlier diagnosis of Type 2 Diabetes





Type 2 Diabetes Pathway

Proforma T2 clinic – for doctor

Proforma	T2 Diabetes	clinic
-----------------	--------------------	--------

Name	Date	Invest
Name	Date	Inve

At diagnosis:

Weightkg BMIkg/m2 HbA1cmol/mmol


Established diagnoses:

	Yes	Maybe	No
T2D			
Hypertension			
Fatty liver			
Hyperlipidaemia			
Microalbuminuria			
Sleep apnoea			

Investigations:


	YES/NO	If abnormal	YES/NO
LFTs with GGT		Abdo US	
		Refer gastro if ALT > 2X ULN	
Random lipids		Fasting lipids	
		if fasting lipids abnormal,	
		focus on lifestyle and then treat	
Blood pressure		If > 95 th centile for height, and sex despite lifestyle for 6 months, start treatment	
Urine ACR		Abnormal if > 3. Repeat in first morning urine (2x). If > 30mg/mol creat, refer to paed nephrologist	
Sleep study		To be decided by resp team.	
Psychol referral		in house psychology	

Inpatient education





Proforma T2 clinic – for patient



Barts Health NES

3arts	Health	NHS
	NHS Trust	

My HbA1c today is previously it was

My Average Blood Glucose mmol/I Finger prick	HbA1c % Clinic 3 month old measurement	HbA1c mmel/mel Clinic 3 month new measurement
6.2	5.5%	37
7.8	6.5%	48
8.2	6.75%	50
8.6	7.0%	53
9.5	7.5%	58
10.1	8.0%	64
11.0	8.5%	70
12.5	9.5%	80

Food Goals	,
Since last clinic I have	
My next goal is	

Exercise Goals:	1
Since last clinic I have	
My next goal is	

Medication Goals
Since last clinic I have
My next goal is

Family Goals	
Since last clinic I have	
My next goal is	
\	